首页> Lancet (London, England)> Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.

导出原文传递

翻译打印收藏纠错

第一作者： Meletios,Dimopoulos

第一单位： National and Kapodistrian University Athens School of Medicine, Athens, Greece.

作者： Meletios,Dimopoulos ^[1] ; Hang,Quach ^[2] ; Maria-Victoria,Mateos ^[3] ; Ola,Landgren ^[4] ; Xavier,Leleu ^[5] ; David,Siegel ^[6] ; Katja,Weisel ^[7] ; Hui,Yang ^[8] ; Zandra,Klippel ^[8] ; Anita,Zahlten-Kumeli ^[8] ; Saad Z,Usmani ^[9]

作者单位： National and Kapodistrian University Athens School of Medicine, Athens, Greece. ^[1] University of Melbourne, St Vincent's Hospital, Fitzroy, VIC, Australia. ^[2] Cancer Research Center, University Hospital Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain. ^[3] Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[4] Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France. ^[5] John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA. ^[6] University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ^[7] Amgen, Thousand Oaks, CA, USA. ^[8] Atrium Health, Charlotte, NC, USA. Electronic address: usmani@atriumhealth.org. ^[9]